Curis (CRIS)

Executive Summary

Curis is a publicly traded biotechnology company focused on developing innovative small-molecule therapeutics for cancer treatment. The company's pipeline includes fimepinostat (CUDC-907), an oral HDAC and PI3K inhibitor in Phase 2 for diffuse intrinsic pontine glioma (DIPG), and emavusertib, a novel IRAK4 inhibitor being evaluated in a Phase 2 combination study with zanubrutinib for chronic lymphocytic leukemia (CLL) and B-cell malignancies. Earlier-stage programs, such as CUDC-101 and CA-170, have been discontinued or completed, allowing Curis to concentrate resources on its most advanced assets. With a modest market capitalization of approximately $23 million, Curis is a high-risk, high-reward investment. The company's near-term value hinges on clinical data from its ongoing Phase 2 trials. Fimepinostat's activity in DIPG, a pediatric brain cancer with limited treatment options, represents a significant unmet need. Meanwhile, the emavusertib-zanubrutinib combination could offer a differentiated approach in CLL. However, the company faces funding challenges given its early-stage pipeline and lack of approved products. Positive data or a strategic partnership could serve as major catalysts.

Upcoming Catalysts (preview)

• H2 2026Interim data from Phase 2 fimepinostat trial in DIPG30% success
• Q1 2027Enrollment update or preliminary efficacy data from Phase 2 emavusertib+zannubrutinib trial in CLL40% success
• TBDPotential partnership, licensing deal, or financing to extend cash runway50% success